https://charts.traderzeitung.de/phases/US30052C1071
string(1443) "{"isin":"US30052C1071","name":"Evolus Inc","stock_id_xnas":7873803,"stock_id_xnys":null,"generated_at":"2026-07-08 14:30:00","days":[{"date":"2026-07-02","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":6.74,"close_at":"2026-07-02 11:00:00","complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":6.89,"close_at":"2026-07-02 21:59:00","complete":true,"perf_pct":2.2255},{"phase":3,"label":"post","from":"22:00","to":"24:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-07-06","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":6.86,"close_at":"2026-07-06 15:28:00","complete":true,"perf_pct":-0.4354},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":6.92,"close_at":"2026-07-06 16:10:00","complete":true,"perf_pct":0.8746},{"phase":3,"label":"post","from":"22:00","to":"24:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-07-07","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":6.955,"close_at":"2026-07-07 21:59:00","complete":true,"perf_pct":0.5058},{"phase":3,"label":"post","from":"22:00","to":"24:00","close":6.95,"close_at":"2026-07-07 22:20:00","complete":true,"perf_pct":-0.0719}]}]}"
Evolus Aktie News & Nachrichten

Evolus Aktie News & Nachrichten

[WKN: A2JDYX | Symbol: EOLS]
Realtimekurs
   
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel
Evolus Chart

TOP-5-Kursziele der Analysten am 05.03.25

AxoGen [US05463X1063]: JMP Securities bekräftigt Buy-Rating und erhöht das Kursziel von 20 auf 26 USD...

Evolus verkündet Rekordumsatz mit Botox-Alternative - neue Dermalfiller für GLP-1-Patienten geplant!

Evolus (EOLS) verfügt mit Jeuveau in den USA über das am schnellsten wachsende Neurotoxin für die...

TOP-5-Kursziele der Analysten am 22.01.25

Evolus Inc. [US30052C1071]: Stifel bekräftigt Buy-Rating mit Kursziel 25 USD (84 % Kurspotenzial) ...

TOP-5-Kursziele der Analysten am 13.09.24

Bank of America (13.09.24) Kursziel 340 CHF (28 % Kurspotenzial) Roche Holding AG [CH0012032048]...

Evolus: Botox-Konkurrent glänzt mit starkem Quartalswachstum und ambitionierten Expansionsplänen

Starkes Quartalswachstum:  Evolus erzielt im 2. Quartal 2024 ein Umsatzplus von 36 % auf 66,9 Mio....

  • 1